Tolerance and pharmacokinetics
We estimate that 13.762 voriconazole nebulizations have been administered. There were no reported AE. There was one case of mild pruritus that did not require treatment withdrawal in a patient who had a history of skin toxicity related to systemic voriconazole.
Voriconazole plasma levels were measured according to clinicians’ criteria. There were 11 voriconazole plasma measurements for 6 patients; it was undetectable in 9 plasma samples from the 4 patients receiving voriconazole by pulmonary route of administration only and two patients receiving systemic voriconazole had plasma levels within the goal range.